company background image
AGL

ANGLE AIM:AGL Stock Report

Last Price

UK£0.78

Market Cap

UK£203.1m

7D

11.8%

1Y

-26.4%

Updated

17 Aug, 2022

Data

Company Financials +
AGL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

AGL Stock Overview

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products.

ANGLE plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ANGLE
Historical stock prices
Current Share PriceUK£0.78
52 Week HighUK£1.64
52 Week LowUK£0.67
Beta0.84
1 Month Change0.97%
3 Month Change-21.21%
1 Year Change-26.42%
3 Year Change9.09%
5 Year Change96.23%
Change since IPO-47.83%

Recent News & Updates

Jul 16
ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Shareholder Returns

AGLGB Medical EquipmentGB Market
7D11.8%-1.2%-0.2%
1Y-26.4%-19.8%-9.0%

Return vs Industry: AGL underperformed the UK Medical Equipment industry which returned -18.5% over the past year.

Return vs Market: AGL underperformed the UK Market which returned -8.2% over the past year.

Price Volatility

Is AGL's price volatile compared to industry and market?
AGL volatility
AGL Average Weekly Movement19.2%
Medical Equipment Industry Average Movement5.6%
Market Average Movement5.3%
10% most volatile stocks in GB Market10.9%
10% least volatile stocks in GB Market2.7%

Stable Share Price: AGL is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: AGL's weekly volatility has increased from 12% to 19% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1994128Andrew David Newlandhttps://angleplc.com

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD multiplex analysis system for routine and focused multiplex analysis of DNA, RNA or protein biomarkers. The company was founded in 1994 and is based in Guildford, the United Kingdom.

ANGLE plc Fundamentals Summary

How do ANGLE's earnings and revenue compare to its market cap?
AGL fundamental statistics
Market CapUK£203.09m
Earnings (TTM)-UK£15.01m
Revenue (TTM)UK£1.01m

200.5x

P/S Ratio

-13.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AGL income statement (TTM)
RevenueUK£1.01m
Cost of RevenueUK£959.00k
Gross ProfitUK£54.00k
Other ExpensesUK£15.07m
Earnings-UK£15.01m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Sep 30, 2022

Earnings per share (EPS)-0.058
Gross Margin5.33%
Net Profit Margin-1,481.93%
Debt/Equity Ratio0%

How did AGL perform over the long term?

See historical performance and comparison